TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05973409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scleral lens
Description: scleral lens with and without hydra-peg coating

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scleral lens
Description: scleral lens with and without hydra-peg coating
Study: NCT06545604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation
Description: Usual care supportive services including nutrition counseling per usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation
Description: Usual care supportive services including nutrition counseling per usual care
Study: NCT06540235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otolith Device Active
Description: The device will be providing different levels of stimulation hypothesized to affect the vestibular system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otolith Device Active
Description: The device will be providing different levels of stimulation hypothesized to affect the vestibular system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Otolith Device Inactive
Description: The device will be providing no stimulation to measure test-retest
Study: NCT06082336

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MagIA IBC test in capillary blood
Description: After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MagIA IBC test in other matrices
Description: Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
Study: NCT05888259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot insole
Description: The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: foot insole
Description: The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
Study: NCT05219565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attractive Targeted Sugar Bait (ATSB)
Description: An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
Study: NCT05631028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
Study: NCT04770103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance recovery
Description: Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural Sway
Description: Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability.
Study: NCT06060301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine 500 MG
Description: The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: The patients will use topical corticosteroids 4 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: The patients will use topical corticosteroids 4 times per day.
Study: NCT04847128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic aerobic exercise
Description: Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
Study: NCT04260217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575 800 mg
Description: APG2575 800 mg
Study: NCT06025110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study: NCT06216561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-HIPEC + LSTA1
Description: LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRS-HIPEC alone
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
Study: NCT06559514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based multi-component psychoeducational inventions (GMC-PEIs)
Description: The participants were randomly assigned to either the experimental group, using a computer-generated list of random numbers.
Study: NCT06380816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4594
Description: Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4594
Description: Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
Study: NCT04870606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proxalutamide (GT0918)
Description: Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo+Standard of care determined by PI and local regulatory
Study: NCT05867017

Intervention type: OTHER
Intervention: Measure of physiologic parameters
Description: Participants will have hepatic muscle and adipose tissue insulin sensitivity tested

Intervention type: OTHER
Intervention: Measure of physiologic parameters
Description: Participants will have hepatic muscle and adipose tissue insulin sensitivity tested

Intervention type: OTHER
Intervention: Measure of physiologic parameters
Description: Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Study: NCT05642286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLVAS® robotic-assisted PCI
Description: ALLVAS® robotic-assisted PCI
Study: NCT06094517

Intervention type: OTHER
Intervention: Interview
Description: Persistent Lower Back Pain Patients on waiting list under going a usual care pathway following referral to Physiotherapy will be interviewed for views on sleep health
Study: NCT05323916

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroproprioceptive facilitation, inhibition
Description: Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology based physical therapy
Description: Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectively managed rehabilitation implementing the recommendations of the World Health Organization
Description: Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
Study: NCT06562738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
Study: NCT04917328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression ultrasound
Description: performing a compression ultrasound
Study: NCT04989491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: One single dose of rituximab intravenously (IV)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: No treatment
Study: NCT06091501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lev Livet
Description: The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lev Livet
Description: The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention.
Study: NCT06139640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Damask Rose Essential Oil
Description: Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
Study: NCT05015023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: A cluster-randomized controlled trial will be conducted.
Study: NCT04705571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MorpheusV Applicator
Description: 1 treatment with the MorpheusV Applicator
Study: NCT05188794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral tap block
Description: In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior tap block
Description: In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
Study: NCT05374343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyroglutamate rongliflozin capsules
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1
Study: NCT06125990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Study Group (SGr)
Description: For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control Group (CGr)
Description: Only institutional conventional rehabilitation was implemented.
Study: NCT06418815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept map group
Description: The intervention group will create a concept map regarding neonatal toxic stress.
Study: NCT05009420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado
Description: avocado served with crackers as breakfast
Study: NCT04034615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells low-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
Study: NCT06064994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: The experimental group received the Smith's version of the mindfulness meditation (Smith, 2005), which is a standardized theory-based intervention found to be effective in improving the different dimensions of health. The Smith's version of the mindfulness meditation (Smith, 2005), includes the following components:~1. Being mindful of breathing (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of thought (5 minutes).~4. Being mindful of sounds (5 minutes).~5. Being mindful of taste (5 minutes)~6. Full meditation
Study: NCT05408221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rulonilimab+Lenvatinib
Description: Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rulonilimab placebo +Lenvatinib
Description: Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
Study: NCT05363800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-3738
Description: HRS-3738 will be administrated per dose level in which the patients are assigned.
Study: NCT05787509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Sustained-release vaginal gel
Description: the treatment time of vaginal progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Sustained-release vaginal gel
Description: the treatment time of vaginal progesterone
Study: NCT04502524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention (New website)
Description: Complete the new website smoking cessation program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention (Standard of care website)
Description: Complete the standard of care website smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive motivational and reminder text messages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive motivational and reminder text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05820438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient.
Study: NCT06319612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline is used. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.